5 citations
,
January 2014 in “Indian Journal of Nephrology” This case report describes a 30-year-old woman with systemic lupus erythematosus who was successfully treated for recurrent hypokalemic periodic quadriparesis after being diagnosed with distal tubular acidosis.
1 citations
,
August 2024 in “Expert Opinion on Drug Safety” This study analyzed data from the FDA Adverse Event Reporting System and found that finasteride had the highest reporting frequency and signal strength for drug-induced erectile dysfunction among 734 drugs, with compound preparations posing higher risks than single ingredients.
This study reported that severe hypothyroidism in two pediatric patients was associated with transient liver and kidney dysfunction, which resolved after beginning levothyroxine treatment.
1 citations
,
September 2025 in “Eye” This pharmacovigilance study found that certain systemic medications, including finasteride, bortezomib, and dupilumab, were disproportionately reported in association with eyelid disorders like blepharitis, meibomian gland dysfunction, and chalazia, suggesting these drugs may contribute to these conditions though benefits might still outweigh the risks.
April 2020 in “BMC endocrine disorders” This case report describes a 65-year-old woman with childhood-onset growth hormone deficiency who developed panhypopituitarism, including late-onset secondary hypoadrenocorticism, affecting her respiratory and renal function.